Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

amgros i/s - phenobarbital - injektionsvæske, opløsning - 10 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

norbrook laboratories ltd. - clotrimazol, dexamethasonacetat, marbofloxacin - øredråber, suspension

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - paclitaxel - koncentrat til infusionsvæske, opløsning - 6 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomid - multipelt myelom - immunosuppressiva - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) er indiceret til behandling af voksne patienter med tidligere ubehandlet myelomatose, der ikke er berettiget til transplantation. lenalidomid overenskomst i kombination med dexamethason er indiceret til behandling af myelomatose hos voksne patienter, der har modtaget mindst én tidligere behandling. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - aprepitant - kapsler, hårde - 125 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

helm ag - lenalidomid - kapsler, hårde - 2,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

helm ag - lenalidomid - kapsler, hårde - 2,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

helm ag - lenalidomid - kapsler, hårde - 2,5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multipelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - lenalidomid - multipelt myelom - immunosuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).